Prazosin – kdc

CLINICAL USE

Alpha-adrenoceptor blocker:Hypertension Congestive heart failure Raynaud’s syndrome Benign prostatic hyperplasia (BPH)

DOSE IN NORMAL RENAL FUNCTION

0.5–20 mg daily in 2–3 divided doses Raynaud’s syndrome, BPH: 0.5–2 mg twice daily

PHARMACOKINETICS

Molecular weight :419.9

%Protein binding :97

%Excreted unchanged in urine :

<10 :

Volume of distribution (L/kg) :1.2–1.5

half-life – normal/ESRD (hrs) :2–4/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Not dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Anaesthetics: enhanced hypotensive effect

Antidepressants: enhanced hypotensive effect with MAOIs

Beta-blockers: enhanced hypotensive effect, increased risk of first dose hypotensive effect

Calcium-channel blockers: enhanced hypotensive effect, increased risk of first dose hypotensive effect

Diuretics: enhanced hypotensive effect, increased risk of first dose hypotensive effect

Moxisylyte: possibly severe postural hypotension when used in combination

Vardenafil, sildenafil and tadalafil: enhanced hypotensive effect – avoid concomitant use

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

Tags: post-by-auto-php